In Silico Clinical Trials Market Size, Share & Trends Analysis Report By Industry (Medical Devices, Pharmaceutical), By Therapeutic Area (Oncology, Infectious Disease, Hematology), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
In SilicClinical Trials Market Growth & Trends
The global in silicclinical trials market size is anticipated treach USD 5.59 billion by 2030, according ta new report by Grand View Research, Inc. The market is projected tgrow at a CAGR of 7.74% from 2025 t2030. Traditional clinical trials require huge expenditure tconduct research. Moreover, a high number of drugs and medical devices fail in the clinical trial owing tthe lack of safety and efficacy, which creates huge losses for the clinical trial sponsors. These factors promote the demand for in silicclinical trials, tunderstand the behavior of drugs or medical devices in humans. In silicclinical trials use simulation techniques tunderstand the efficacy and safety of a drug or medical device.
This reduces the chances of adverse reactions, thus, improving the safety and efficacy of research studies. The market players are making significant investments tprovide new treatments tthe people. For instance, in June 2021, In silicMedicine raised USD 255 million in funding tboost its R&D for drug discovery, through in silicstudies. The demand for in silicclinical trials was alsimproved during the pandemic as there was a temporary shutdown of clinical research sites and several studies for vaccines and therapeutic agents for COVID-19 were performed through in silicresearch models. Such actions are likely thave a positive impact on market growth.
In SilicClinical Trials Market Report Highlights
In SilicClinical Trials Market Growth & Trends
The global in silicclinical trials market size is anticipated treach USD 5.59 billion by 2030, according ta new report by Grand View Research, Inc. The market is projected tgrow at a CAGR of 7.74% from 2025 t2030. Traditional clinical trials require huge expenditure tconduct research. Moreover, a high number of drugs and medical devices fail in the clinical trial owing tthe lack of safety and efficacy, which creates huge losses for the clinical trial sponsors. These factors promote the demand for in silicclinical trials, tunderstand the behavior of drugs or medical devices in humans. In silicclinical trials use simulation techniques tunderstand the efficacy and safety of a drug or medical device.
This reduces the chances of adverse reactions, thus, improving the safety and efficacy of research studies. The market players are making significant investments tprovide new treatments tthe people. For instance, in June 2021, In silicMedicine raised USD 255 million in funding tboost its R&D for drug discovery, through in silicstudies. The demand for in silicclinical trials was alsimproved during the pandemic as there was a temporary shutdown of clinical research sites and several studies for vaccines and therapeutic agents for COVID-19 were performed through in silicresearch models. Such actions are likely thave a positive impact on market growth.
In SilicClinical Trials Market Report Highlights
- The medical device segment dominated the market in 2024 owing tthe fact that the majority of in silictrials are performed for medical devices globally
- The phase II segment accounted for the largest market revenue share in 2024
- The oncology therapeutic area segment accounted for the largest market revenue share in 2024
- The cancer clinical trials have high chances of incurring adverse effects on patients, which promotes the demand for in silictrials for cancer
- North America held the largest revenue share in 2024 due tthe presence of several global players operating in the market
- In addition, a significant number of in silictrials are performed in the U.S., which further contributes tthe growth of the regional market
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. IN SILICO CLINICAL TRIALS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Cost Efficiency Associated with In silico Clinical Trials Compared to Traditional Clinical Trials
3.2.1.2. Growing Trend of Eliminating/Reducing Animal Testing
3.2.1.3. Increasing Technological Advancement in the In silico Clinical Trials Market
3.2.2. Market restraint analysis
3.2.2.1. Protein Flexibility Issues, Molecule Conformation and Promiscuity May Hinder Accurate Predictions, thus limiting its Adoption
3.2.2.2. Limited Awareness in the Developing Economies
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. IN SILICO CLINICAL TRIALS MARKET: INDUSTRY ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global In Silico Clinical Trials Market: Industry Movement Analysis
4.3. Global In Silico Clinical Trials Size & Trend Analysis, by Industry, 2018 to 2030 (USD Million)
4.4. Medical Devices
4.4.1. Medical devices market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Pharmaceutical
4.5.1. Pharmaceutical market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. IN SILICO CLINICAL TRIALS MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global In Silico Clinical Trials Market: Therapeutic Area Movement Analysis
5.3. Global In Silico Clinical Trials Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
5.4. Oncology
5.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Infectious Disease
5.5.1. Infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Hematology
5.6.1. Hematology market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Cardiology
5.7.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Dermatology
5.8.1. Dermatology market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Neurology
5.9.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Diabetes
5.10.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. IN SILICO CLINICAL TRIALS MARKET: PHASE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Global In Silico Clinical Trials Market: Phase Movement Analysis
6.3. Global In Silico Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
6.4. Phase I
6.4.1. Phase I market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Phase II
6.5.1. Phase II market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Phase III
6.6.1. Phase III market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Phase IV
6.7.1. Phase IV market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. IN SILICO CLINICAL TRIALS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. North America
7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.3.2. U.S.
7.3.2.1. Key country dynamics
7.3.2.2. Competitive scenario
7.3.2.3. Regulatory framework
7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Key country dynamics
7.3.3.2. Competitive scenario
7.3.3.3. Regulatory framework
7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.3.4. Mexico
7.3.4.1. Key country dynamics
7.3.4.2. Competitive scenario
7.3.4.3. Regulatory framework
7.3.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.2. UK
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Regulatory framework
7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. Germany
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Regulatory framework
7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. France
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Regulatory framework
7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Italy
7.4.5.1. Key country dynamics
7.4.5.2. Competitive scenario
7.4.5.3. Regulatory framework
7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.6. Spain
7.4.6.1. Key country dynamics
7.4.6.2. Competitive scenario
7.4.6.3. Regulatory framework
7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.7. Denmark
7.4.7.1. Key country dynamics
7.4.7.2. Competitive scenario
7.4.7.3. Regulatory framework
7.4.7.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.8. Sweden
7.4.8.1. Key country dynamics
7.4.8.2. Competitive scenario
7.4.8.3. Regulatory framework
7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.9. Norway
7.4.9.1. Key country dynamics
7.4.9.2. Competitive scenario
7.4.9.3. Regulatory framework
7.4.9.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.2. Japan
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Regulatory framework
7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. China
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Regulatory framework
7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. India
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Regulatory framework
7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Australia
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Regulatory framework
7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. South Korea
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Regulatory framework
7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Thailand
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Regulatory framework
7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.2. Brazil
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Regulatory framework
7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Regulatory framework
7.6.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.2. South Africa
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Regulatory framework
7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Regulatory framework
7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.4. UAE
7.7.4.1. Key country dynamics
7.7.4.2. Competitive scenario
7.7.4.3. Regulatory framework
7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key country dynamics
7.7.5.2. Competitive scenario
7.7.5.3. Regulatory framework
7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Company Market Position Analysis, 2024
8.3. Company Profiles
8.3.1. Certara, Inc.
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Service benchmarking
8.3.1.4. Strategic initiatives
8.3.2. Novadiscovery Sas
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Service benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Insilico Medicine, Inc.
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Service benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Dassault Systemes SE
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Service benchmarking
8.3.4.4. Strategic initiatives
8.3.5. GNS Healthcare Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Service benchmarking
8.3.5.4. Strategic initiatives
8.3.6. The AnyLogic Company
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Service benchmarking
8.3.6.4. Strategic initiatives
8.3.7. InSilicoTrials
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Service benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Immunetrics Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Service benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Nuventra Pharma Sciences
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Service benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Abzena Ltd.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Service benchmarking
8.3.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. IN SILICO CLINICAL TRIALS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Cost Efficiency Associated with In silico Clinical Trials Compared to Traditional Clinical Trials
3.2.1.2. Growing Trend of Eliminating/Reducing Animal Testing
3.2.1.3. Increasing Technological Advancement in the In silico Clinical Trials Market
3.2.2. Market restraint analysis
3.2.2.1. Protein Flexibility Issues, Molecule Conformation and Promiscuity May Hinder Accurate Predictions, thus limiting its Adoption
3.2.2.2. Limited Awareness in the Developing Economies
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. IN SILICO CLINICAL TRIALS MARKET: INDUSTRY ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global In Silico Clinical Trials Market: Industry Movement Analysis
4.3. Global In Silico Clinical Trials Size & Trend Analysis, by Industry, 2018 to 2030 (USD Million)
4.4. Medical Devices
4.4.1. Medical devices market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Pharmaceutical
4.5.1. Pharmaceutical market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. IN SILICO CLINICAL TRIALS MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global In Silico Clinical Trials Market: Therapeutic Area Movement Analysis
5.3. Global In Silico Clinical Trials Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
5.4. Oncology
5.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Infectious Disease
5.5.1. Infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Hematology
5.6.1. Hematology market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Cardiology
5.7.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Dermatology
5.8.1. Dermatology market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Neurology
5.9.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Diabetes
5.10.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. IN SILICO CLINICAL TRIALS MARKET: PHASE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Global In Silico Clinical Trials Market: Phase Movement Analysis
6.3. Global In Silico Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
6.4. Phase I
6.4.1. Phase I market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Phase II
6.5.1. Phase II market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Phase III
6.6.1. Phase III market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Phase IV
6.7.1. Phase IV market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 7. IN SILICO CLINICAL TRIALS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. North America
7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.3.2. U.S.
7.3.2.1. Key country dynamics
7.3.2.2. Competitive scenario
7.3.2.3. Regulatory framework
7.3.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
7.3.3. Canada
7.3.3.1. Key country dynamics
7.3.3.2. Competitive scenario
7.3.3.3. Regulatory framework
7.3.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
7.3.4. Mexico
7.3.4.1. Key country dynamics
7.3.4.2. Competitive scenario
7.3.4.3. Regulatory framework
7.3.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.2. UK
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Regulatory framework
7.4.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.3. Germany
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Regulatory framework
7.4.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.4. France
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Regulatory framework
7.4.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.5. Italy
7.4.5.1. Key country dynamics
7.4.5.2. Competitive scenario
7.4.5.3. Regulatory framework
7.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.6. Spain
7.4.6.1. Key country dynamics
7.4.6.2. Competitive scenario
7.4.6.3. Regulatory framework
7.4.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.7. Denmark
7.4.7.1. Key country dynamics
7.4.7.2. Competitive scenario
7.4.7.3. Regulatory framework
7.4.7.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.8. Sweden
7.4.8.1. Key country dynamics
7.4.8.2. Competitive scenario
7.4.8.3. Regulatory framework
7.4.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.4.9. Norway
7.4.9.1. Key country dynamics
7.4.9.2. Competitive scenario
7.4.9.3. Regulatory framework
7.4.9.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.2. Japan
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Regulatory framework
7.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. China
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Regulatory framework
7.5.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. India
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Regulatory framework
7.5.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Australia
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Regulatory framework
7.5.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. South Korea
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Regulatory framework
7.5.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Thailand
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Regulatory framework
7.5.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.2. Brazil
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Regulatory framework
7.6.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Regulatory framework
7.6.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.2. South Africa
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Regulatory framework
7.7.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Regulatory framework
7.7.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.4. UAE
7.7.4.1. Key country dynamics
7.7.4.2. Competitive scenario
7.7.4.3. Regulatory framework
7.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key country dynamics
7.7.5.2. Competitive scenario
7.7.5.3. Regulatory framework
7.7.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Company Market Position Analysis, 2024
8.3. Company Profiles
8.3.1. Certara, Inc.
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Service benchmarking
8.3.1.4. Strategic initiatives
8.3.2. Novadiscovery Sas
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Service benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Insilico Medicine, Inc.
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Service benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Dassault Systemes SE
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Service benchmarking
8.3.4.4. Strategic initiatives
8.3.5. GNS Healthcare Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Service benchmarking
8.3.5.4. Strategic initiatives
8.3.6. The AnyLogic Company
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Service benchmarking
8.3.6.4. Strategic initiatives
8.3.7. InSilicoTrials
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Service benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Immunetrics Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Service benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Nuventra Pharma Sciences
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Service benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Abzena Ltd.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Service benchmarking
8.3.10.4. Strategic initiatives
